Biocon denies plans to sell $1.5 billion generic API business

Biocon API business: Biocon has refuted claims of considering the sale of its generic active pharmaceutical ingredient (API) business, valued at $1.5 billion, to alleviate its debt burden. A company spokesperson clarified they were not assessing divestment options or seeking advice from bankers, countering an ET report based on insights from familiar sources.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news